Pamplona Capital Management acquires Parexel International
Pamplona Capital Management has completed its acquisition of biopharmaceutical services company, Parexel. Pamplona has acquired all outstanding shares of Parexel for USD88.10 per share in cash. The transaction was approved overwhelmingly by stockholders on September 15, with more than 98 per cent of votes cast in favour. Parexel stock will